BCG Vaccine USP + Isoniazid + Rifampin
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tuberculosis
Conditions
Tuberculosis
Trial Timeline
Dec 6, 2022 → Dec 1, 2023
NCT ID
NCT05592223About BCG Vaccine USP + Isoniazid + Rifampin
BCG Vaccine USP + Isoniazid + Rifampin is a phase 1 stage product being developed by Merck for Tuberculosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05592223. Target conditions include Tuberculosis.
What happened to similar drugs?
3 of 5 similar drugs in Tuberculosis were approved
Approved (3) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05592223 | Phase 1 | Completed |
Competing Products
20 competing products in Tuberculosis